
Easier to Prescribe Opioids Than Buprenorphine – Experts Lament Patient Barriers to Medication-Assisted Treatment
A panel of experts recently appeared before a Medicaid and

A panel of experts recently appeared before a Medicaid and

In mid-March, the FDA approved the postpartum depression drug brexanolone,

If you’re reading this post, you likely already know the

Health and Human Services Secretary Alex Azar announced this November

On November 29th, a webinar series organized by the National

This September, the National Institute on Drug Abuse (NIDA) released

Update: On Wednesday, October 24, 2018, President Trump officially signed

AZZLY® is joining the National Association of Addiction Treatment Providers
For individuals struggling with opioid use disorder, accessing medication-assisted treatment (MAT) can be a challenging and frustrating process. Experts lament the barriers patients face in getting prescribed buprenorphine, a medication that helps reduce cravings and withdrawal symptoms. Despite its effectiveness, buprenorphine is often overshadowed by the easier prescribing process for opioids.
The recent FDA approval of Zulresso, a drug for postpartum depression, has raised concerns over its high cost. While the approval of new medications is a positive step in addressing mental health issues, the affordability of these drugs remains a major obstacle for many patients. These challenges highlight the importance of addressing access and cost barriers in medication therapy to ensure that individuals receive the treatment they need.
For individuals struggling with opioid use disorder, accessing medication-assisted treatment (MAT) can be a challenging and frustrating process. Experts lament the barriers patients face in getting prescribed buprenorphine, a medication that helps reduce cravings and withdrawal symptoms. Despite its effectiveness, buprenorphine is often overshadowed by the easier prescribing process for opioids.
The recent FDA approval of Zulresso, a drug for postpartum depression, has raised concerns over its high cost. While the approval of new medications is a positive step in addressing mental health issues, the affordability of these drugs remains a major obstacle for many patients. These challenges highlight the importance of addressing access and cost barriers in medication therapy to ensure that individuals receive the treatment they need.